Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurofibromatosis 2.

Michael E Baser1, D Gareth R Evans, David H Gutmann

  • 1baser@earthlink.net

Current Opinion in Neurology
|January 25, 2003
PubMed
Summary
This summary is machine-generated.

Patients with neurofibromatosis 2 (NF2) benefit from specialized care, as treatment center type impacts mortality risk. Tumor growth varies significantly, necessitating individualized treatment strategies and targeted therapies for schwannomas and meningiomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nested pediatric low-grade glioma cerebral organoid avatars reveal glutamatergic neuron stromal growth dependency.

Genes & development·2026
Same author

Differences in Optic Pathway Glioma Prevalence Among Children with Neurofibromatosis Type 1.

The Journal of pediatrics·2026
Same author

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics·2026
Same author

Nested ecosystems theory for conceptualizing brain tumors.

Disease models & mechanisms·2026
Same author

Time trends in the male to female ratio for autism incidence: population based, prospectively collected, birth cohort study.

BMJ (Clinical research ed.)·2026
Same author

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Neuro-oncology advances·2026

Area of Science:

  • Oncology
  • Genetics
  • Neurology

Background:

  • Neurofibromatosis 2 (NF2) is a genetic disorder characterized by tumor development.
  • Key features include schwannomas, meningiomas, and ependymomas.
  • Understanding NF2 pathogenesis is crucial for effective management.

Purpose of the Study:

  • To review recent clinical and molecular research on neurofibromatosis 2 (NF2).
  • To discuss the implications of this research for clinical practice and future research directions.

Main Methods:

  • Literature review of recent clinical and molecular studies on NF2.
  • Analysis of findings related to patient outcomes, tumor growth, and molecular mechanisms.

Main Results:

Related Experiment Videos

  • Treatment at specialty centers is associated with reduced mortality in NF2 patients.
  • Vestibular schwannoma growth rates are highly variable and age-dependent.
  • Mouse models and in-vitro studies have identified key molecules (e.g., CD44, paxillin) regulating merlin, offering therapeutic targets.

    • Conclusions:

    • NF2 patients require referral to specialized treatment centers for optimal care.
    • Individualized management is essential due to variable tumor growth rates.
    • Targeted therapies for schwannomas and meningiomas are becoming feasible due to advancements in understanding merlin regulation and development of mouse models.